

Application of Nanoparticles in the Treatment of Ovarian Cancer: A Review of Emerging Strategies for Targeted Therapy

Maryam Aghdaki¹  and Sima Kamkari² 

¹Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

²Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Article Info	ABSTRACT
<p>Article type: Review Article</p> <p>Article History: Received: 23 Sep 2025 Revised: 21 Jan 2026 Accepted: 21 Jan 2026 Published Online: 20 Apr 2026</p> <p> Correspondence to: Sima Kamkari</p> <p>Email: Sima.kamkari@gmail.com</p>	<p>Objective: Ovarian cancer remains highly lethal, primarily due to late-stage diagnosis and the limitations of conventional therapies, which are often associated with systemic toxicity and limited tumor specificity. Nanoparticles, owing to their nanoscale dimensions, high surface-to-volume ratio, and capacity for surface functionalization, offer improved drug delivery and precise tumor targeting. This review provides a comprehensive summary of the principal types of nanoparticles employed in ovarian cancer therapy, with an emphasis on their mechanisms of action and therapeutic efficacy.</p> <p>Methods: This narrative review synthesizes findings from experimental and preclinical studies investigating nanoparticle-based interventions in ovarian cancer. Relevant publications were identified through systematic searches of established scientific databases, including PubMed, Scopus, and Google Scholar. Studies focusing on nanoparticle design, targeting strategies, drug-loading efficiency, and therapeutic outcomes were critically evaluated and analyzed.</p> <p>Results: A diverse range of nanostructures has been investigated for the treatment of ovarian cancer. These include magnetoelectric $\text{CoFe}_2\text{O}_4@ \text{BaTiO}_3$ nanoparticles; poly(lactic-co-glycolic acid) (PLGA)-based nanoplateforms co-delivering cisplatin and HER2-targeted antibodies; biodegradable periodic mesoporous organosilica (PMO) nanoparticles loaded with doxorubicin; polymer-based immunotargeted nanoparticles (NPs-Tx-HER); mesoporous silica nanoparticles (MSNPs); poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles encapsulating paclitaxel; PARP1-targeted small interfering RNA (siRNA) nanocarriers; folate-conjugated lipid nanoparticles; cathepsin B-responsive doxorubicin prodrug nanoparticles; and PTP@SR-717 nanocomplexes. Across in vitro and in vivo models, these nanosystems have demonstrated enhanced tumor-specific accumulation, improved intracellular drug delivery, reduced systemic toxicity, and potentiation of chemotherapeutic and immunotherapeutic efficacy.</p> <p>Conclusion: Nanoparticle-based therapies represent a significant advancement in ovarian cancer treatment, enabling precise tumor targeting and controlled drug release. This approach minimizes the systemic toxicity commonly associated with conventional chemotherapy while enhancing anticancer efficacy. When integrated with cytotoxic agents, gene-silencing molecules, or monoclonal antibodies, nanoparticle platforms facilitate the development of personalized and more effective therapeutic strategies. Ultimately, these innovations hold considerable potential to improve clinical outcomes and enhance patients' quality of life.</p> <p>Keywords: Nanoparticles; Ovarian cancer therapy; Chemotherapy; Nanomedicine; Targeted drug delivery</p>
<p>How to cite this paper Aghdaki M, Kamkari S. Application of Nanoparticles in the Treatment of Ovarian Cancer: A Review of Emerging Strategies for Targeted Therapy. <i>Plant Biotechnology Persa</i>. 2026; 8(2): 170-184.</p>	

Introduction

Gynecologic diseases particularly malignancies of the female reproductive tract exert a profound impact on women's health, longevity, and overall quality of life. Delayed diagnosis remains a critical obstacle in the management of these cancers, as detection at advanced stages is consistently associated with reduced survival rates. Consequently, preventive strategies and early diagnostic interventions are of paramount importance [1-6]. Among gynecologic malignancies, ovarian cancer occupies a particularly aggressive and devastating position.

Ovarian cancer is recognized as one of the most prevalent and fatal malignancies affecting women worldwide. Owing to its insidious onset and nonspecific early symptoms, it is frequently diagnosed at advanced stages, which substantially contributes to its high mortality rate [7]. Despite significant advances in oncologic research and therapeutic innovation, ovarian cancer continues to represent a formidable global clinical challenge [8].

The etiology of ovarian cancer is complex and multifactorial, reflecting an interplay among genetic predisposition, environmental exposures, and hormonal influences [9]. Germline mutations in critical DNA repair genes most notably *BRCA1* and *BRCA2* are well-established risk factors that significantly increase lifetime susceptibility to the disease [10]. In addition to hereditary determinants, several epidemiologic variables have been implicated, including a positive family history, age over 50 years, nulliparity, and prolonged exposure to hormone replacement therapy [11]. Collectively, these factors underscore the heterogeneous and multifaceted nature of ovarian carcinogenesis.

At the molecular level, the pathophysiology of ovarian cancer is characterized by uncontrolled cellular proliferation driven by cumulative genetic and epigenetic alterations [12]. Disruptions in key regulatory signaling pathways, including PI3K/AKT and TP53, play central roles in tumor initiation and progression [13]. Aberrant activation

of these pathways promotes sustained proliferative signaling, resistance to apoptosis, enhanced cellular migration, and eventual metastatic dissemination. Such molecular dysregulation also contributes to therapeutic resistance, which remains a major barrier to effective long-term disease control.

Conventional treatment strategies for ovarian cancer typically involve a combination of cytoreductive surgery and systemic chemotherapy, with radiotherapy reserved for selected clinical scenarios [14]. Surgical intervention aims to remove the primary tumor mass and achieve maximal cytoreduction, a factor consistently associated with improved clinical outcomes. Systemic chemotherapy most commonly platinum-based regimens combined with taxanes remains the cornerstone of first-line and adjuvant therapy [15]. However, these modalities are frequently limited by systemic toxicity, off-target effects, cumulative adverse reactions, and the emergence of drug resistance.

In recent years, nanotechnology has emerged as a transformative approach in oncology, offering innovative solutions to longstanding therapeutic limitations. The application of nanoparticles in ovarian cancer treatment has attracted substantial attention as a promising strategy within the broader field of cancer nanomedicine [16]. Nanoparticles exhibit distinctive physicochemical properties, including nanoscale dimensions, high surface-to-volume ratios, and the capacity for surface functionalization and efficient drug encapsulation [17]. These attributes enable enhanced tumor targeting and controlled drug release, thereby improving therapeutic precision.

Importantly, nanoparticle-based delivery systems can facilitate preferential accumulation of anticancer agents within tumor tissues through both passive and active targeting mechanisms, while minimizing collateral damage to healthy cells [18]. Beyond drug delivery, these platforms may help overcome multidrug resistance, modulate the tumor microenvironment, and reduce recurrence risk through multimodal therapeutic strategies [19]. Such advantages position nanotechnology as

a compelling adjunct or potential alternative to conventional treatment paradigms.

Given the considerable promise of nanoparticle-mediated interventions in ovarian cancer and their potential to mitigate the adverse effects associated with standard therapies, continued investigation in this field is both timely and warranted [20]. The present article aims to comprehensively examine recent advances in nanoparticle design and application for ovarian cancer therapy, with particular emphasis on their mechanisms of action, therapeutic efficacy, and prospective clinical implications.

Methodology

This review aimed to systematically analyze and evaluate the various nanoparticles employed in the treatment of ovarian cancer. Data were extracted from peer-reviewed articles available in major scientific databases, including PubMed, Scopus, and Google Scholar. The research process was conducted as follows:

Literature

An initial search was performed using combinations of keywords such as “nanoparticles ovarian cancer therapy,” “targeted drug delivery ovarian cancer,” and “magnetic nanoparticles ovarian cancer” to identify relevant publications. Searches were limited to studies published in English and focused on experimental, preclinical, or clinical investigations.

Study

Articles specifically addressing the application of nanoparticles in ovarian cancer therapy were selected for inclusion. Studies lacking experimental data or sufficient scientific rigor were excluded from the analysis. Both *in vitro* and *in vivo* studies were considered to provide a comprehensive overview of therapeutic potential.

Quality

The methodological quality of the selected studies was evaluated based on study design, reliability of results, and robustness of scientific documentation. Only studies providing

reproducible experimental data from laboratory, preclinical, or clinical investigations were included.

Data

The review focused on diverse nanoparticle types including magnetic, liposomal, polymeric, and mesoporous systems and their therapeutic applications in ovarian cancer. Mechanisms of drug delivery and tumor targeting were comprehensively evaluated, with particular attention to treatment specificity, reduction of systemic toxicity, and enhancement of therapeutic efficacy.

Cellular effects of nanoparticles were also examined, including their influence on tumor growth, induction of apoptosis, and promotion of reactive oxygen species (ROS) production. The historical progression of nanoparticle uses in ovarian cancer from early applications to recent innovations was critically analyzed.

Innovative developments in targeted nanoparticle design were highlighted, including nanoparticles co-delivering chemotherapeutic agents, gene-silencing molecules, or monoclonal antibodies, as well as nanoparticles engineered with intrinsic antitumor properties.

Finally, after compiling and analyzing the selected studies, the findings regarding the efficacy of nanoparticles in ovarian cancer therapy were synthesized to provide an integrated perspective on their clinical potential.

Results

This review analyzed the diverse types of nanoparticles employed in ovarian cancer therapy, including magnetic, liposomal, polymeric, metallic, and other specialized formulations. These nanosystems have demonstrated substantial therapeutic potential due to their unique physicochemical properties, enabling precise tumor targeting, controlled drug release, and reduced systemic toxicity.

Nanoparticles facilitate direct delivery of anticancer agents to tumor sites. Many are functionalized with specific targeting ligands, such as folate or HER2 antibodies, allowing selective recognition and uptake by ovarian cancer cells. This targeted delivery enhances therapeutic efficacy while minimizing off-target effects compared with conventional treatments.

The antitumor effects of nanoparticles are multifaceted. They can induce apoptosis, promote the generation of reactive oxygen species (ROS), inhibit tumor growth, and modulate the tumor microenvironment. Certain nanoparticles also enhance chemosensitivity, restoring or amplifying the effectiveness of standard chemotherapeutic regimens.

Preclinical and in vitro studies consistently demonstrate that nanoparticles can suppress tumor progression, reduce metastasis, and improve overall therapeutic outcomes. Hybrid nanoparticles, such as PLGA-PTX and DDP-Ola@HR systems which combine chemotherapy and radiotherapy in a single platform have shown

particularly promising results, effectively reduced tumor volume while enhancing antitumor activity.

The therapeutic efficacy of nanoparticles has been evaluated across a variety of models, including human ovarian cancer cell lines (e.g., SKOV-3), murine preclinical models, and patient-derived xenografts. Collectively, these studies underscore the potential of nanoparticle-based strategies to improve clinical outcomes in ovarian cancer therapy.

Detailed information on nanoparticle types, physicochemical characteristics, therapeutic mechanisms, and observed effects in ovarian cancer treatment is summarized in Table 1.

Table 1: Types of Nanoparticles Used in Ovarian Cancer Therapy, Their Physicochemical Characteristics, Therapeutic Mechanisms, and Effects

Nanoparticle Type (Size & Properties)	Therapeutic Target & Mechanism	Observed Effects	Model	Reference
CoFe ₂ O ₄ @BaTiO ₃ (30 nm)	SKOV-3 targeting via DC magnetic field	Nano-electroporation, complete tumor cell eradication	Cellular (SKOV-3)	[21]
PLGA-Cisplatin-HER2 antibody	HER2+ targeting	Enhanced uptake, increased cytotoxicity vs free drug	Cellular	[22]
Biodegradable PMO-Doxorubicin	Targeted drug delivery	Tumor eradication, minimal organ toxicity	CAM	[23]
NPs-Tx-HER	Paclitaxel + HER2 targeting	Superior antitumor effect, prolonged survival	Murine	[24]
Mesoporous silica nanoparticles (MSNPs)	Reduced protein adsorption	↑50% cytotoxicity	In vitro	[25]
PHBV-PTX	Polymer degradation-dependent release	Significant cell death	Human cellular	[26]
PARP1-targeted siRNA	Inhibition of BRCA1-deficient growth	Increased survival	Murine	[27]
Folate-targeted lipid nanoparticles	Folate receptor-mediated targeting	↑ ROS, apoptosis induction	Xenograft	[28]
Cathepsin B-sensitive DOX prodrug	Enzyme-triggered release	Tumor growth inhibition, reduced toxicity	Peritoneal carcinomatosis	[29]
PTP@SR-717	STING activation	Enhanced cisplatin efficacy	In vitro	[30]
Albumin-Albendazole (200-300 nm)	Growth inhibition	Selective cytotoxicity	In vitro	[31]

Fe ₃ O ₄ -Silica fluorescent (47 nm)	SKOV-3 targeting	MR/fluorescence imaging	Cellular	[32]
CRLX101	HIF1 α suppression	Synergistic effect with Bevacizumab	Preclinical	[33]
HA@PFG-Cisplatin	pH-triggered release	Apoptosis induction	PDX	[34]
HA-PLGA-PTX + siFAK	Overcoming chemoresistance	Tumor growth suppression	Human/PDX	[35]
miR497/TP-HENPs	PI3K/AKT/mTOR inhibition	Increased apoptosis	In vitro	[36]
Mito-Her2@RSHM	Mitoxantrone delivery	83% tumor suppression	Animal	[37]
PLGA-siMDR1/BCL2	Drug-resistance inhibition	\uparrow Sensitivity to PTX/DDP	Resistant cellular	[38]
NiNPs@F. officinalis (16-49 nm)	Plant-derived anticancer effect	Proliferation inhibition	In vitro	[39]
Cu ₂ O-Camellia sinensis	Anticancer activity	High uptake in SW-626 cells	In vitro	[40]
NiNPs-Alhagi maurorum (20-36 nm)	Anticancer	Reduced OVCAR-3 survival	In vitro	[41]
CNPpTCP/si(c-fos)	Light-activated	Pt(II) release	In vitro/In vivo	[42]
siRNA/FA-PEG-COL (~200 nm)	Folate receptor targeting	HIF-1 α suppression	In vivo	[43]
Collagen-poly(3-APBA) (~81 nm)	DOX delivery	Sustained release	Cellular/Animal	[44]
Polyamine-coated IL-12 liposomes	Immune stimulation	Increased survival	Murine	[45]
SLN-ODN anti-STAT3	STAT3 inhibition	Apoptosis induction	In vitro	[46]
Py-TPE/siRNA@PMP	PTX resistance	Restored chemosensitivity	Cellular/Xenograft	[47]

MSNP-HA-siTWIST	TWIST inhibition	Tumor burden reduction	Murine	[48]
MION (~20 nm)	DDP sensitization	↑ ROS	OVCAR-3/SKOV-3	[49]
PLGA-PRINT-Docetaxel	mEZH2 inhibition	Tumor weight reduction	Preclinical	[50]
PLGA-PTX	Controlled release	Anticancer effect	Cellular	[51]
Lipid-PTX-EGFR	HEY targeting	↓ Tumor volume 50%	Xenograft	[52]
NLC-Verteporfin	Photodynamic therapy	Growth inhibition with laser	Murine	[53]
Iron oxide-HER2 affibody	HER2+ targeting	Metastasis inhibition	Human xenograft	[54]
PLGA-PEG-TEM1-SHK (120-250 nm)	Endothelium targeting	Prolonged release	In vitro	[55]
PLGA-CBD (~240 nm)	Intraperitoneal delivery	Lower IC50	CAM	[56]
Iron-FA/SiO ₂ /PEG	Folate receptor targeting	Specific cellular uptake	In vitro	[57]
AgNPs-Sal (16-20 nm)	Apoptosis/autophagy	High cytotoxicity	In vitro	[58]
Silica-based NO-releasing NPs	Ras inhibition	Tumor growth suppression	In vitro	[59]
Silica/Polystyrene (10-50 nm)	Cellular uptake analysis	Size-dependent cell death	In vitro	[60]
AuNPs-Cisplatin	EMT inhibition	CSC reduction	Animal	[61]
LbL polyaspartate/HA coating	Preferential targeting	High specificity	Animal/Spheroid	[62]

DDP-Ola@HR	PI3K/AKT/mTOR inhibition	Tumor growth & metastasis suppression	DDP-resistant	[63]
Folate-PTXL-Yttrium-90	Chemo + radiotherapy	Metastasis reduction	Murine	[64]
CNPPtCP/si(c-fos) (optimized)	Platinum-resistant therapy	Synergistic effect	In vivo	[65]
siRNA/FA-PEG-COL (advanced)	Targeted gene therapy	Enhanced tumor accumulation	In vivo	[66]

Table 1 provides a comprehensive summary of the diverse nanoparticles investigated for ovarian cancer therapy. Nanoparticles are increasingly employed in modern oncology due to their distinctive physicochemical properties, particularly their ability to selectively target malignant cells and reduce systemic toxicity.

Types of Nanoparticles and Mechanisms

Magnetoelectric nanoparticles (CoFe₂O₄@BaTiO₃): These nanoparticles utilize their magnetic properties to be guided to tumor sites via a DC magnetic field, enabling precise delivery to ovarian cancer cells.

PLGA-based nanoparticles loaded with cisplatin and HER2 antibodies: Designed for HER2-positive cells, this platform enhances intracellular drug uptake and cytotoxicity compared to free cisplatin.

Biodegradable PMO nanoparticles encapsulating doxorubicin: These systems provide targeted delivery to ovarian cancer cells while minimizing toxicity to healthy tissues.

Many nanoparticle platforms are engineered with multiple targeting mechanisms, including HER2, CD44, and PARP1, often combined with controlled-release systems. Certain formulations also integrate combination therapies, simultaneously delivering chemotherapeutic and radiotherapeutic agents to improve therapeutic outcomes.

Theranostic Applications
Several nanoparticles serve dual roles as therapeutic and diagnostic agents. For instance, Fe₃O₄ nanoparticles coated with fluorescent silica enable both magnetic resonance (MR) and fluorescence imaging, allowing real-time monitoring of biodistribution, tumor uptake, and treatment response. Such theranostic capabilities provide valuable insights for personalized treatment planning.

Therapeutic Effects

Tumor growth inhibition: Nanoparticles consistently suppress proliferation across cellular and animal models.

Enhanced chemosensitivity: Platforms such as PLGA-PTX and PTP@SR-717 increase the responsiveness of ovarian cancer cells to chemotherapeutic agents like paclitaxel and cisplatin.

ROS generation and apoptosis induction: Many nanoparticles elevate reactive oxygen species (ROS), promoting apoptosis in cancer cells.

Reduced systemic toxicity: Compared with conventional chemotherapy, nanoparticle-based therapies demonstrate substantially lower off-target effects and improved tolerability.

Experimental Models

Cellular models: Ovarian cancer cell lines, including SKOV-3 and OVCAR-8, are used to evaluate cytotoxicity, cellular uptake, and intracellular drug release.

Animal models: Murine studies, xenografts, and patient-derived xenografts (PDX) assess in vivo efficacy, tumor regression, and pharmacokinetics.

Human studies: A limited number of studies have evaluated nanoparticle effects in human tumor samples, providing translational insights into clinical potential.

Implications and Future Directions
Nanoparticles have demonstrated considerable therapeutic promise, including efficacy against chemoresistant ovarian cancer subtypes. Future research should focus on enhancing targeting precision, multifunctional capabilities, and integration with emerging technologies such as advanced imaging and personalized therapies. Combining nanoparticles with chemotherapy, radiotherapy, or gene therapy may further improve treatment efficacy while reducing invasiveness.

Overall, the evidence summarized in Table 1 underscores the remarkable potential of nanoparticle-based strategies for ovarian cancer therapy. Their unique physicochemical properties particularly selective tumor targeting and minimized systemic toxicity position nanoparticles as highly effective tools in advancing cancer treatment and improving patient outcomes.

Discussion

Epithelial ovarian cancer remains one of the most formidable challenges in gynecologic oncology due to late-stage diagnosis, extensive peritoneal dissemination, and frequent development of resistance to platinum- and taxane-based chemotherapies [67]. Standard treatment typically involves cytoreductive surgery followed by platinum- or carboplatin-based chemotherapy combined with paclitaxel. However, disease recurrence and acquired drug resistance are common in a substantial proportion of patients. In this context, nanomedicine has emerged as a promising strategy, offering the potential to improve the therapeutic index by enhancing tumor specificity while minimizing systemic toxicity [67].

A key focus in recent research has been the use of actively targeted nanoparticles. For instance, PLGA nanoparticles conjugated with HER2 antibodies and polymer-immunotargeted systems (NPs-Tx-HER) have demonstrated the ability to bind selectively to overexpressed receptors on tumor cells. This targeted approach increases drug uptake in cancer cells while sparing healthy tissues [68]. These platforms not only augment the efficacy of paclitaxel and cisplatin but have also been associated with improved survival in animal models. Such findings underscore the potential of combining nanocarriers with monoclonal antibodies as a step toward personalized ovarian cancer therapy [69].

Tumor microenvironment-responsive nanoparticles have also shown promise in overcoming drug resistance. Cathepsin B-sensitive doxorubicin prodrug nanoparticles and pH-responsive release systems enable selective drug release within the tumor milieu. This targeted release increases intratumoral drug concentration while reducing systemic side effects, such as doxorubicin-induced cardiotoxicity [70,71]. Furthermore, magnetoelectric $\text{CoFe}_2\text{O}_4@ \text{BaTiO}_3$ nanoparticles, when stimulated via nanoelectroporation under a magnetic field, enhance cell membrane permeability and achieve complete eradication of SKOV-3 cells in vitro, presenting a potential adjunct to conventional chemotherapy [70,71].

In the realm of gene therapy, the delivery of siRNA targeting genes such as PARP1, MDR1, BCL2, or STAT3 via lipid or polymeric nanoparticles opens new avenues for inhibiting survival and resistance pathways [72]. Simultaneous blockade of drug efflux mechanisms (P-gp/MRP2) and anti-apoptotic factors significantly sensitizes resistant ovarian cancer cells to cisplatin and paclitaxel. These results highlight the importance of multi-targeted approaches in managing chemoresistant ovarian cancer. Additionally, nanoparticles engineered to modulate key signaling pathways, including PI3K/AKT/mTOR or Ras, have been shown to suppress tumor proliferation, migration, and metastasis [73].

Another notable strategy is the use of nanoparticles in combinatorial and multifunctional therapies. Systems co-delivering cisplatin and olaparib, with heparin coating and cRGD ligands, have concurrently targeted DNA repair mechanisms and drug resistance pathways [74]. Similarly, combining chemotherapy with radiotherapy (e.g., yttrium-90-containing nanoparticles) or photodynamic therapy (lipid-based nanoparticles loaded with verteporfin) enhances antitumor effects and reduces recurrence risk. These combinatorial strategies demonstrate that

nanoparticles can function not only as drug carriers but also as multifunctional theranostic platforms [75].

Despite promising results in cellular models, CAM, xenografts, and PDX studies, clinical translation faces significant challenges. Tumor heterogeneity, variability in receptor expression, patient-specific EPR effects, long-term safety concerns, and potential nanoparticle accumulation toxicity remain critical barriers [76]. In addition, scalable production, formulation stability, and standardization of physicochemical properties are essential prerequisites for clinical trials [76].

Overall, the findings from this review indicate that nanoparticles, through active and passive targeting, controlled drug release, simultaneous drug and gene delivery, and integration with immunotherapy or physical modalities, hold substantial potential for enhancing ovarian cancer treatment. The future likely lies in the design of smart, multi-stimuli-responsive systems, molecularly guided combination therapies, and theranostic platforms. Achieving this goal will require rigorous phase I–III clinical trials and comprehensive evaluation of safety and efficacy in large patient populations.

Conclusion

Nanoparticles represent a novel therapeutic platform in ovarian cancer treatment, improving the therapeutic index through precise tumor targeting and reduced systemic toxicity. Smart nanocarriers with controlled release and dual drug-gene delivery capabilities play a pivotal role in overcoming drug resistance and modulating tumor signaling pathways. Evidence from cellular, preclinical, and xenograft models demonstrates effective tumor growth inhibition, metastasis suppression, and enhanced survival compared to conventional therapies. The integration of nanoparticles with chemotherapy, radiotherapy, gene therapy, and immunotherapy opens new horizons for multi-modal and personalized treatment approaches. Despite challenges in clinical translation, the development of safe and standardized nanoplatforms has the potential to advance ovarian cancer therapy toward more precise, effective, and less toxic interventions.

Acknowledgments

The authors express their gratitude to the Clinical Research Development Unit of Imam Khomeini Hospital, Urmia University of Medical Sciences, for assistance with English editing.

Authors' Contribution

Conceptualization: Sima Kamkari and Maryam Aghdaki

Data curation: Maryam Aghdaki

Formal analysis: Sima Kamkari

Funding acquisition: Sima Kamkari and Maryam Aghdaki

Investigation: Maryam Aghdaki

Methodology: Sima Kamkari

Project administration:

Resources: Sima Kamkari and Maryam Aghdaki

Software: Sima Kamkari

Supervision: Maryam Aghdaki

Validation: Sima Kamkari

Visualization: Sima Kamkari

Writing–original draft: Sima Kamkari and Maryam Aghdaki

Writing–review & editing: Sima Kamkari and Maryam Aghdaki

Aghdaki

Competing Interests

None declared.

Funding

None.

References

- Kamkari S, Soufizadeh Balaneji S. The Role of Medicinal Plants in Relieving Menopausal Symptoms: A Traditional Iranian Medicine Perspective. *Plant Biotechnol Persa*. 2026;8. Available from: <http://pbp.medilam.ac.ir/article-1-382-en.html>
- Najib FS, Izanloo E, Aghdaki M, Khansalar S, Fattahi MJ, Oveisi Z, et al. Stromal Cell-Derived Factor1 Genetic Variation at Locus 801 in Patients with Endometrial Cancer. *Middle East J Cancer*. 2025;16(2):181-8.
- Kamkari S, Sadat Najib F. Abortifacient Medicinal Plants: A Review of Toxic Herbs During Pregnancy. *Plant Biotechnol Persa*. 2026;8. Available from: <http://pbp.medilam.ac.ir/article-1-378-en.html>
- Faraji A, Aghdaki M, Hessami K, Hosseinkhani A, Roozmeh S, Asadi N, et al. Episiotomy wound healing by *Commiphora myrrha* and *Boswellia carteri* in primiparous women: A randomized controlled trial. *J Ethnopharmacol*. 2021;264:113396.
- Aghdaki M, Kamkari S. Probiotics as a Therapeutic Strategy in Ovarian Cancer: Insights from Preclinical and Clinical Evidence. *Plant Biotechnol Persa*. 2026;8. Available from: <http://pbp.medilam.ac.ir/article-1-392-en.html>
- Salehi AM, Shahbazi F, Garavand R, Kamkari S, Jenabi E. Global socioeconomic inequalities in breast, cervical, ovarian, and uterine cancers incidence, mortality, disability-adjusted life year's rates: a relative concentration index analysis. *BMC Womens Health*. 2025;25(1):433.
- Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. *Semin Oncol Nurs*. 2019;35(2):151-6.
- Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. *Lancet*. 2014;384(9951):1376-88.
- Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. *Clin Obstet Gynecol*. 2012;55(1):3-23.
- Nomura H, Iwasa N, Yoshihama T, Nanki Y, Aoki D. Epidemiology and etiology of ovarian cancer. In: *Frontiers in Ovarian Cancer Science*. Singapore: Springer; 2017. p. 1-13.
- Barber HR. Ovarian carcinoma: etiology, diagnosis, and treatment. Springer; 2012.
- Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. *Am J Obstet Gynecol*. 2015;213(3):262-7.
- Furuya M. Ovarian cancer stroma: pathophysiology and the roles in cancer development. *Cancers (Basel)*. 2012;4(3):701-24.
- Lee JM, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. *Cancer*. 2019;125:4623-9.
- Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. *Maturitas*. 2014;77(2):128-36.
- Aghebati-Maleki A, Dolati S, Ahmadi M, Baghbanzhadeh A, Asadi M, Fotouhi A, et al. Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. *J Cell Physiol*. 2020;235(3):1962-72.
- Ding H, Zhang J, Zhang F, Xu Y, Liang W, Yu Y. Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends. *Drug Deliv*. 2022;29(1):3218-32.
- Kreuter J. Nanoparticles. In: *Colloidal Drug Delivery Systems*. CRC Press; 2014. p. 231-53.
- Horikoshi SA, Serpone NI. Introduction to nanoparticles. *Microwaves in Nanoparticle Synthesis*. 2013;1-24.
- Anselmo AC, Mitragotri S. Nanoparticles in the clinic. *Bioeng Transl Med*. 2016;1(1):10-29.
- Guduru R, Liang P, Runowicz C, Nair M, Atluri V, Khizroev S. Magneto-electric nanoparticles to enable field-controlled high-specificity drug delivery to eradicate ovarian cancer cells. *Sci Rep*. 2013;3:2953.
- Dominguez-Rios R, Sanchez-Ramirez DR, Ruiz-Saray K, Ocegüera-Basurto PE, Almada M, Juárez J, et al. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. *Colloids Surf B Biointerfaces*. 2019;178:199-207.
- Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, et al. Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. *Sci Rep*. 2018;8:8524.
- Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. *J Control Release*. 2010;144(3):324-31.
- Sanchez-Salcedo S, Vallet-Regí M, Shahin SA, Glackin CA, Zink JJ. Mesoporous core-shell silica nanoparticles with anti-fouling properties for ovarian cancer therapy. *Chem Eng J*. 2018;340:114-24.
- Vilos C, Morales FA, Solar PA, Herrera NS, Gonzalez-Nilo FD, Aguayo DA, et al. Paclitaxel-PHBV nanoparticles and

- their toxicity to endometrial and primary ovarian cancer cells. *Biomaterials*. 2013;34(16):4098-108.
27. Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. *Proc Natl Acad Sci U S A*. 2011;108(2):745-50.
 28. Liu Y, Chen S, Sun J, Zhu S, Chen C, Xie W, et al. Folate-targeted and oxygen/indocyanine green-loaded lipid nanoparticles for dual-mode imaging and photodynamic/photothermal therapy of ovarian cancer. *Mol Pharm*. 2019;16(10):4104-20.
 29. Kim J, Shim MK, Cho YJ, Jeon S, Moon Y, Choi J, et al. Safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. *Biomaterials*. 2021;279:121189.
 30. Fu H, Guo X, Fang F, Zhou C, Chen Y, Zhang X, et al. STING pathway activation with cisplatin polyprodrug nanoparticles for chemo-immunotherapy in ovarian cancer. *J Control Release*. 2025;381:113565.
 31. Noorani L, Pourgholami MH, Liang M, Morris DL, Stenzel M. Albendazole loaded albumin nanoparticles for ovarian cancer therapy. *Eur J Nanomed*. 2014;6(4):227-36.
 32. Wang L, Neoh KG, Kang ET, Shuter B. Multifunctional polyglycerol-grafted Fe₃O₄@SiO₂ nanoparticles for targeting ovarian cancer cells. *Biomaterials*. 2011;32(8):2166-73.
 33. Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, et al. Translational impact of nanoparticle–drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. *Clin Cancer Res*. 2015;21(4):808-18.
 34. Li G, Shi S, Tan J, He L, Liu Q, Fang F, et al. Highly efficient synergistic chemotherapy and magnetic resonance imaging for targeted ovarian cancer therapy using hyaluronic acid-coated coordination polymer nanoparticles. *Adv Sci (Weinh)*. 2024;11(41):2309464.
 35. Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, et al. CD44-targeting PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. *Cancer Res*. 2018;78(21):6247-56.
 36. Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 overcomes chemoresistant ovarian cancer. *J Nanobiotechnol*. 2022;20:50.
 37. Risnayanti C, Jang YS, Lee J, Ahn HJ. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. *Sci Rep*. 2018;8:1-2.
 38. Huang Y, Zhu C, Xie R, Ni M. Green synthesis of nickel nanoparticles using *Fumaria officinalis* as a novel chemotherapeutic drug for ovarian cancer. *J Exp Nanosci*. 2021;16(1):368-81.
 39. Dou L, Zhang X, Zangeneh MM, Zhang Y. Efficient biogenesis of Cu₂O nanoparticles using *Camellia sinensis* leaf extract: evaluation of cytotoxic and anti-human ovarian cancer properties. *Bioorg Chem*. 2021;106:104468.
 40. Yuan C, Jiang B, Xu X, Wan Y, Wang L, Chen J. Anti-human ovarian cancer and cytotoxicity effects of nickel nanoparticles green-synthesized by *Alhagi maurorum* leaf extract. *J Exp Nanosci*. 2022;17(1):113-25.
 41. Yuan C, Jiang B, Xu X, Wan Y, Wang L, Chen J. Anti-human ovarian cancer and cytotoxicity effects of nickel nanoparticles green-synthesized by *Alhagi maurorum* leaf aqueous extract. *J Exp Nanosci*. 2022 Dec 31;17(1):113-25.
 42. Zhang Q, Kuang G, He S, Lu H, Cheng Y, Zhou D, Huang Y. Photoactivatable prodrug-backboned polymeric nanoparticles for efficient light-controlled gene delivery and synergistic treatment of platinum-resistant ovarian cancer. *Nano Lett*. 2020 Apr 6;20(5):3039-49.
 43. Li TS, Yawata T, Honke K. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid–poly (ethylene glycol)–chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy. *Eur J Pharm Sci*. 2014 Feb 14;52:48-61.
 44. Jiang H, Liang G, Dai M, Dong Y, Wu Y, Zhang L, Xi Q, Qi L. Preparation of doxorubicin-loaded collagen-PAPBA nanoparticles and their anticancer efficacy in ovarian cancer. *Ann Transl Med*. 2020 Jul;8(14):880.
 45. Pires IS, Covarrubias G, Gomerding VF, Backlund C, Nombera Bueno E, Billingsley MM, Pryor M, Shanker A, Gordon E, Wu S, Pickering AJ. IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer. *Nat Mater*. 2025 Oct 31;1-3.
 46. Ma Y, Zhang X, Xu X, Shen L, Yao Y, Yang Z, Liu P. STAT3 decoy oligodeoxynucleotides-loaded solid lipid nanoparticles induce cell death and inhibit invasion in ovarian cancer cells. *PLoS One*. 2015 Apr 29;10(4):e0124924.
 47. Wu J, Wang Q, Dong X, Xu M, Yang J, Yi X, Chen B, Dong X, Wang Y, Lou X, Xia F. Biocompatible AIEgen/p-glycoprotein siRNA@ reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer. *Theranostics*. 2021 Jan 27;11(8):3710.
 48. Shahin SA, Wang R, Simargi SI, Contreras A, Echavarria LP, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JJ. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. *Nanomedicine (Lond)*. 2018 Jun;14(4):1381-94.
 49. Gokduman K. Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: an in vitro study. *Nanomedicine*. 2019 Dec;14(24):3177.
 50. Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. *Mol Cancer Ther*. 2014 Jul;13(7):1750-7.
 51. Dragulska SA, Acosta Santiago M, Swierczek S, Chuang L, Camacho-Vanegas O, Camacho SC, Padron-Rhenals MM,

- Martignetti JA, Mieszawska AJ. Synthesis and Characterization of Poly (Lactic-Co-Glycolic Acid)-Paclitaxel (PLGA-PTX) Nanoparticles Evaluated in Ovarian Cancer Models. *Pharmaceutics*. 2025 May 23;17(6):689.
52. Zhai J, Luwor RB, Ahmed N, Escalona R, Tan FH, Fong C, Ratcliffe J, Scoble JA, Drummond CJ, Tran N. Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer. *ACS Appl Mater Interfaces*. 2018 Jul 2;10(30):25174-85.
 53. Michy T, Massias T, Bernard C, Vanwonderghem L, Henry M, Guidetti M, Royal G, Coll JL, Texier I, Jossierand V, Hurbin A. Verteporfin-loaded lipid nanoparticles improve ovarian cancer photodynamic therapy in vitro and in vivo. *Cancers (Basel)*. 2019 Nov 8;11(11):1760.
 54. Satpathy M, Wang L, Zielinski RJ, Qian W, Wang YA, Mohs AM, Kairdolf BA, Ji X, Capala J, Lipowska M, Nie S. Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles. *Theranostics*. 2019 Jan 24;9(3):778.
 55. Matthaiou EI, Barar J, Sandaltzopoulos R, Li C, Coukos G, Omid Y. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. *Int J Nanomedicine*. 2014 Apr 15;9:1855-70.
 56. Fraguas-Sánchez AI, Torres-Suárez AI, Cohen M, Delie F, Bastida-Ruiz D, Yart L, Martin-Sabroso C, Fernández-Carballido A. PLGA nanoparticles for the intraperitoneal administration of CBD in the treatment of ovarian cancer: In Vitro and In Ovo assessment. *Pharmaceutics*. 2020 May 9;12(5):439.
 57. Kraiss A, Wortmann L, Hermanns L, Feliu N, Vahter M, Stucky S, Mathur S, Fadeel B. Targeted uptake of folic acid-functionalized iron oxide nanoparticles by ovarian cancer cells in the presence but not in the absence of serum. *Nanomedicine (Lond)*. 2014 Oct;10(7):1421-31.
 58. Zhang XF, Gurunathan S. Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy. *Int J Nanomedicine*. 2016 Aug 2;11:3655-75.
 59. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfisch MH. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. *Mol Pharm*. 2010 Jun 7;7(3):775-85.
 60. Ekkapongpisit M, Giovia A, Follo C, Caputo G, Isidoro C. Biocompatibility, endocytosis, and intracellular trafficking of mesoporous silica and polystyrene nanoparticles in ovarian cancer cells: effects of size and surface charge groups. *Int J Nanomedicine*. 2012 Jul 31;7:4147-58.
 61. Xiong X, Arvizo RR, Saha S, Robertson DJ, McMeekin S, Bhattacharya R, Mukherjee P. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. *Oncotarget*. 2014 Jul 11;5(15):6453-64.
 62. Correa S, Boehnke N, Barberio AE, Deiss-Yehiely E, Shi A, Oberlton B, Smith SG, Zervantonakis I, Dreaden EC, Hammond PT. Tuning nanoparticle interactions with ovarian cancer through layer-by-layer modification of surface chemistry. *ACS Nano*. 2020 Jan 23;14(2):2224-37.
 63. Liang X, Yang Y, Huang C, Ye Z, Lai W, Luo J, Li X, Yi X, Fan JB, Wang Y, Wang Y. cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer. *J Control Release*. 2023 Apr 1;356:691-701.
 64. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ. Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. *Biomaterials*. 2011 Nov;32(33):8548-54.
 65. Zhang Q, Kuang G, He S, Lu H, Cheng Y, Zhou D, Huang Y. Photoactivatable prodrug-backboned polymeric nanoparticles for efficient light-controlled gene delivery and synergistic treatment of platinum-resistant ovarian cancer. *Nano Lett*. 2020 Apr 6;20(5):3039-49.
 66. Li TS, Yawata T, Honke K. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly (ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy. *Eur J Pharm Sci*. 2014 Feb 14;52:48-61.
 67. Lengyel E. Ovarian cancer development and metastasis. *Am J Pathol*. 2010 Sep;177(3):1053-64.
 68. Wang Y, Pasternak M, Sathiyamoorthy K, Kolios MC. Anti-HER2 PLGA-PEG polymer nanoparticle containing gold nanorods and paclitaxel for laser-activated breast cancer detection and therapy. *Biomed Opt Express*. 2021 Mar 18;12(4):2171-85.
 69. Al-Taie A, Özcan Bülbül E. A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches. *J Drug Target*. 2024 Jan 2;32(1):45-56.
 70. Shim N, Jeon SI, Yang S, Park JY, Jo M, Kim J, Choi J, Yun WS, Kim J, Lee Y, Shim MK. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy. *Biomaterials*. 2022 Oct;289:121806.
 71. Zhong YJ, Shao LH, Li YA. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy. *Int J Oncol*. 2013 Feb;42(2):373-83.
 72. Sargazi S, Mukhtar M, Rahdar A, Barani M, Pandey S, Díez-Pascual AM. Active targeted nanoparticles for delivery of poly (ADP-ribose) polymerase (PARP) inhibitors: a preliminary review. *Int J Mol Sci*. 2021 Sep 25;22(19):10319.
 73. Alemi SF, Pourhassan MM, Kalan ME, Mehdipour A, Aliyari SZ, Ebrahimi KA. Targeting the PI3K/Akt/mTOR signaling pathway: Applications of nanotechnology. *[Journal/Year details missing]*
 74. Mensah LB, Morton SW, Li J, Xiao H, Quadir MA, Elias KM, Penn E, Richson AK, Ghoroghchian PP, Liu J, Hammond PT. Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer. *Bioeng Transl Med*. 2019 May;4(2):e10131.
 75. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer:

drug delivery, image-guided therapy, and multifunctional platforms. *Appl Biochem Biotechnol.* 2011 Dec;165(7):1628-51.

76. Saman S, Srivastava N, Yasir M, Chauhan I. A comprehensive review on current treatments and challenges involved in the treatment of ovarian cancer. *Curr Cancer Drug Targets.* 2024 Feb 1;24(2):142-66.